Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Large-scale IgM and IgG SARS-CoV-2 serological screening among healthcare workers with a low infection prevalence based on nasopharyngeal swab tests in an Italian university hospital: Perspectives for public health

Luigi Vimercati a, b,⁎, Pasquale Stefanizzi c, Luigi De Maria a, b, Antonio Caputi a, b, Domenica Cavone a, b, Marco Quarato a, b, Loreto Gesualdo d, Pier Luigi Lopalco e, Giovanni Migliore f, Stefania Sponselli a, b, Giusi Graziano c, Angela Maria Vittoria Larocca c, Silvio Tafuri c

a Interdisciplinary Department of Medicine, University of Bari, Bari, Italy
b Occupational Medicine Unit, University Hospital of Bari, Bari, Italy
c Department of Biomedical Science and Human Oncology, University of Bari, Bari, Italy
d President, School of Medicine, University of Bari, Bari, Italy
e Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa, Italy
f Hospital Director, University Hospital of Bari, Bari, Italy

ARTICLE INFO

Keywords:
Serological screening
COVID-19
Healthcare workers

ABSTRACT

Background: Healthcare workers (HCWs) are highly exposed to SARS-CoV-2 infection given their specific tasks. The IgG-IgM serological assay has demonstrated good accuracy in early detection in symptomatic patients, but its role in the diagnosis of asymptomatic patients is uncertain. The aim of our study was to assess IgM and IgG prevalence in sera in a large cohort of HCWs previously subjected to Nasopharyngeal swab test (NST) after accurate risk assessment due to positive COVID-19 patient exposure during an observation period of 90 days.

Methods: 2407 asymptomatic HCWs that had close contact with COVID-19 patients in the period between April 8th and June 7th were screened with NST based on the RT-PCR method. In parallel, they underwent large-scale chemiluminescence immunoassays involving IgM-IgG serological screening to determine actual viral spread in the same cohort.

Results: During the 90-day observation period, 18 workers (0.75%) resulted positive for SARS-CoV-2 infection at the NST, whereas the positivity rates for IgM and IgG were 11.51% and 2.37%, respectively (277 workers). Despite high specificity, serological tests were inadequate for detecting SARS-CoV-2 infection in patients with previous positive NST results (IgM and IgG sensitivities of 27.78% and 50.00%, respectively).

Conclusions: These findings indicate a widespread low viral load of SARS-CoV-2 among hospital workers. However, serological screening showed very low sensitivity with respect to NST in identifying infected workers, and negative IgG and IgM results should not exclude the diagnosis of COVID-19. IgG-IgM chemiluminescence immunoassays could increase the diagnosis of COVID-19 only in association with NST, and this association is considered helpful for decision-making regarding returning to work.

1. Background

SARS-CoV-2 is a huge challenge for healthcare workers worldwide. The specific tasks of healthcare workers include daily contact with infected people, and the Hospital Health Administration is forced to rapidly adapt work conditions to avoid nosocomial cluster (Karuppiah et al., 2020). However, after the first large European wave of infection between March and May, the most recent literature focuses attention on...
asymptomatic patients as an effective and efficient source of contagion (Bhattacharya et al., 2020); the ability to intercept these patients is crucial to avoid new clusters and lockdown measures.

To date, among all available diagnostic methods for detecting SARS-CoV-2, real-time reverse transcription polymerase chain reaction (RT-PCR) using respiratory samples is the gold standard for COVID-19 diagnosis, but the combination of IgM and IgG antibodies offer increased sensitivity (Bojer et al., 2020). Moreover, Deeks et al. affirmed that IgM antibody detection is a sensitive and specific tool to diagnose recent SARS-CoV-2 infection at least 15 days after close contact with an infected individual if NST was negative (Deeks et al., 2020).

To date, automated chemiluminescent immunoassay (CLIA) is the most validated serological test and seems to increase RT-PCR sensitivity (Soleimani et al., 2020). Recently, high sensitivity rates were described in IgM and IgG CLIA determination (88% and 100% after 12 days of symptom onset) (Padoan et al., 2020; Nicol et al., 2020). On the other hand, rapid detection SARS-CoV-2 antibody tests, e.g., lateral flow immunoassays (LFIs), seem to have lower accuracy (Guedez-Lopez et al., 2020; Zhang et al., 2020); in particular, the immunochromatographic antibody test is burdened by the high incidence of false positive results of IgG (Shibata et al., 2020).

The longitudinal profile of IgM and IgG kinetics revealed seroconversion for both within 6 days withpike times of 18 and 23 days, respectively (Shu et al., 2020). A positive IgG and/or IgM result in a single sample collected 2 weeks after symptoms in patients who were negative based on NST suggests SARS-CoV-2 infection; however, today, minimal evidence is available for the asymptomatic population (Long et al., 2020).

The aim of this study was to assess IgM and IgG prevalence in sera in a large cohort of HCWs previously subjected to NST after accurate risk assessment due to positive COVID-19 patient exposure during an observation period of 90 days.

2. Methods

Study group. All HCWs of the University Hospital of Bari, Italy underwent a preventive protocol that required them to undergo a NST in case of close contact with COVID-19 patients or evidence of SARS-CoV-2 symptoms onset (anosmia, ageusia, fever, asthenia, sore throat, rhinorrhea, cough, diarrhea, and dyspnea). All HCWs subject to NST, after 14–21 days, underwent sera collection for SARS-CoV-2 IgM and IgG determination. Occupational risk assessment was performed according to Italian Guidelines for Biological Occupational Risk and CDC guidance (Centre for Disease Control, 2019; Alessio et al., 2005). The three risk categories were high, medium, and low.

Specimen collection and analysis. All the selected workers were submitted to a collection of nasopharyngeal SWAB specimens by trained staff following adequate standard operating procedures (SOPs), and during the collection, all specimens were handled carefully according to World Health Organization (WHO) criteria (World Health Organization, 2018; recommended Surveillance; Guideline for the collect, 2000). The specimens underwent Nucleic Acid Amplification Tests (NAAT) for COVID-19. This method is based on the detection of unique sequences of virus RNA by real-time Reverse-Transcription Polymerase Chain Reaction (rRT-PCR). HCWs who had non-PPE guarded contact with confirmed COVID patients were placed in home isolation and therefore NST was performed at their home. On the other hand HCWs who had PPE-guarded contact have continued to work and therefore NST was performed at the Hospital Virology Laboratory. Biological safety requirements were adhered to in both scenarios.

Sero logical test. IgG and IgM serological tests were performed according the Abbott method by the Abbott Company, which won the contract proclaimed by the Italian Government as an emergency provision for serological COVID tests.

Serum samples were inserted into an Abbott Architect Instrument i2000sr using the Abbott-specific assay based on chemiluminescent microparticle immunoassay with a positivity cutoff of 1.40 AU/ml for IgG and 1.0 AU/ml for IgM.

Statistical analysis. Data were collected using an Excel file (Microsoft Corporation (2016)). Absolute prevalence and percentage were calculated for positive results for NTS and serological tests. Descriptive statistics were performed to define the baseline characteristics of the study sample. The results are reported as the mean ± sd and frequency with percentages for continuous and categorical variables, respectively. To assess the role of different individual (sex, age) and occupational (biological risk, operative units, job titles) variables on the results of SWAB nasopharyngeal tests and serological tests, separate univariate logistic regressions were performed. Multiple logistic regression analyses were used to investigate the risk of observing serological positive tests after positive nasopharyngeal SWAB results (as an indicator of infection of COVID virus) by adjusted for sex, age, biological risk, selected job titles and operative units. The risk, both in univariate and multiple regressions, was expressed as an odds ratio (OR) with the relative 95% confidence interval (CI). All the results with a p-value<0.05 were considered statistically significant. The diagnostic accuracy of serological tests compared with the SWAB test was also evaluated. The measures considered included sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). All analyses were conducted with SAS software (version 9.4).

3. Results

During the 90-day observation period, 2407 of 5750 HCWs (41.86%) referred to at least one close contact with COVID-19 patients and underwent NST and serological determination in a period between the

| Table 1 | Sociodemographic, professional and clinical characteristics of the HCW_s enrolled. |
|---------|---------------------------------------------------------------------------------|
| N       | 2407                                                                            |
| AGE     | 45.67 ± 11.96                                                                  |
| GENDER  |                                                                                 |
| M       | 1047 (43.5%)                                                                   |
| F       | 1360 (56.5%)                                                                   |
| JOB TITLE |                                                                                 |
| Physician | 831 (34.52%)                                                                    |
| Nurse    | 859 (33.61%)                                                                    |
| Support operator | 547 (14.42%)                                                                  |
| Healthcare professions | 53 (2.2%)                       |
| Other    | 367 (15.25%)                                                                   |
| OPERATIVE UNIT |                                                             |
| Other clinical units | 1373 (57.16%)                                                                   |
| Infectious diseases | 70 (2.91%)                                                                      |
| Emergency room | 107 (4.45%)                                                                    |
| Intensive care unit, anesthesiology | 357 (14.86%)                                                                  |
| COVID units | 118 (4.91%)                                                                    |
| Nonclinical units (no contact with patients) | 377 (15.7%)                      |
| BIOLOGICAL RISK |                                                     |
| Low risk  | 281 (11.78%)                                                                    |
| Medium risk | 1452 (60.85%)                                                                  |
| High risk | 653 (27.37%)                                                                   |
| SWAB     |                                                                                 |
| Negative | 2389 (99.25%)                                                                   |
| Positive | 18 (0.75%)                                                                      |
| TEST IGM |                                                                                 |
| Negative | 2130 (88.49%)                                                                   |
| Positive | 277 (11.51%)                                                                    |
| TEST IgG |                                                                                 |
| Negative | 2350 (97.63%)                                                                   |
| Positive | 57 (2.37%)                                                                      |
14th and 21st days after NST. Table 1 shows all sociodemographic, professional and clinical characteristics of the HCWs enrolled. Participants were middle-aged (45.67 ± 11.96) and predominantly women (56.5%). A large part of the sample (approximately 70%) was composed of physicians and nurses (60.85%) mostly exposed, during their daily practice, to a medium biological risk, i.e. HCWs that provide direct assistance to patients, in the absence of procedures that generate aerosols, in the patient room/ward. The absolute prevalence of HCWs with a nasopharyngeal SWAB test positive for SARS-COV-2 infection was 18 out of 2470 (0.75%). The prevalence of a positive IgM serological test was 277 HCWs out of 2470 (11.51%), and the prevalence for IgG was 57 out of 2470 (2.37%). Table 2 shows the association between the HCWs and the three main outcomes of the survey. The only determinant associated with the positive SWAB test was job title (p-value = 0.027); subjects with SARS-COV-2 infection were most frequently physicians (72.2%).

The IgM test results were associated with age (p-value = 0.0004), biological risk (p-value = 0.0004), job title (p-value = 0.0187) and operative units (p-value=0.0001). In particular, seropositive workers were younger (43.3 ± 12.2), were more exposed to medium (67.0%) biological risk and were more frequently physicians (40.8%) working in clinical operative units (66.5%) compared with workers testing negative. The IgG test results were not associated with any of the determinants considered. Four HCWs remained asymptomatic until healing. The contact tracing protocol revealed that 17 of 18 HCWs had been in close contact with COVID-19 cases in non-workplace settings (households, schools, group-living and other social environments); only one, a 56-year-old physician, was in close contact with a COVID-19 patient at work. Univariate analyses were performed to express the previous associations in terms of odds ratios with 95% confidence intervals. The results are shown in Table 3. The probability of obtaining positive results on the nasopharyngeal SWAB test was higher for physicians compared with all other job titles (OR = 4.99 (1.77–14.06)).

Older HCWs were at a lower probability of being positive on the IgM test (OR = 0.98 (0.97–0.99)). The workers exposed to a low biological risk exhibited a lower probability of being positive on the IgM test (OR = 0.31 (0.17–0.57)). The physicians and the workers of the clinical operative units exhibited an increased probability of obtaining positive IgM test results [OR = 1.36 (1.05–1.75) and OR = 1.54 (1.18–2), respectively]. Unexpectedly, working at infectious disease units is a protective factor (OR = 0.22 (0.05–0.91)). The probability of a positive IgG results was directly associated with the age expressed as years [OR = 1.03 (1–1.05)] and with the job of the support operators [OR = 1.97 (1.07–3.65)].

Table 4 presents the multivariate analysis results. The probability of positive IgM test results after positive nasopharyngeal SWAB test results as an indicator of infection adjusted for sex, age, biological risk, selected job titles and operative units was significantly high [OR = 2.91 (1.01–8.39)]. The probability of observing positive IgG tests after a positive nasopharyngeal SWAB test adjusted for the same variables was also relevant [OR = 77.32 (26.07–229.34)]. The multivariate analyses confirmed that age, biological risk (medium and high) and operative units (infectious diseases) are factors associated with IgM test positivity. Age was confirmed as a risk factor for IgG test positivity. Table 5 presents the accuracy of serological tests (both IgM and IgG) using the SWAB test as the gold standard.

|  | SWAB |  |  |  |
|---|---|---|---|---|
|  | NEGATIVE (%) | POSITIVE (%) | PVALUE |  |
| N | 2389 (99.3) | 18 (0.7) | 0.4113 |  |
| Age | 45.7 ± 12.0 | 43.2 ± 11.8 | 0.8676 |  |
| Gender | M | 1041 (43.6) | 6 (33.3) | 0.8676 |  |
| Biological risk | Low risk | 281 (11.9) | 0 (0.0) | 0.3918 |  |
| Job title | Physician | 818 (34.2) | 13 (72.2) | 0.027 |  |
| Operative unit | Other | 367 (15.4) | 0 (0.0) | 0.0004 |  |

Table 2 Association between HCWs and survey outcome.

4. Discussion

In the 90-day observation period, all HCWs subjected to combined screening were enrolled after accurate risk assessment postexposure to confirmed COVID patients. According to European Center of Disease Control (EDCC) guidelines (European Center for Diseas), all HCWs with high biological risk were equipped with a full Personal Protective Equipment (PPE) kit (gloves, safety goggles, FFP2 protection mask or better, disposable gown), and the gold standard test (RT-PCR) was mandatory after each close contact. Only a negative test result would allow HCWs to keep working, and serological tests were reserved for epidemiological purposes (Center for Disease Contro, 2019).

After double screening, we found an unexpectedly high serological prevalence of SARS-CoV-2 infection despite a low rate of RT-PCR positivity. IgM positivity was higher in each HCW category (nurse, physician, SHOs) with respect to IgG prevalence.

Considering the high specificity of the chemiluminescence immunoassay found in previous studies (Padoan et al., 2020) and calculated in our using test as the gold standard, these results could indicate the
existence of numerous undiagnosed COVID-19 cases among HCWs in the assistant setting; infected people likely remained asymptomatic, which could explain the trouble in identifying these workers through NST (Liu et al., 2020). Moreover, the large difference in positive results between serological and nasopharyngeal tests could indicate many sources of unknown exposure to SARS-CoV-2 despite the implementation of preventive measures. An Italian cross-sectional study highlighted that approximately half of infected HCWs had no significant personal history of SARS-CoV-2 exposure, suggesting that many sources of contagion were unapparent. Thus, the exclusive use of RT-PCR screening is complex and not very useful (Lahner et al., 2020). Moreover, an appropriate window period seems to be essential to enhance the sensitivity of serological tests, increasing the gap in the positive result rate with respect to RT-PCR. In a multicenter retrospective study in Wuhan, China, 47% of SARS-CoV-2-infected people, who were mostly asymptomatic, were diagnosed with serological tests after negative RT-PCR (Tang et al., 2020), as demonstrated by Clarke and colleagues. A high seroprevalence of SARS-CoV-2 antibodies was noted in asymptomatic or

Table 3
Univariate analyses.

|          | SWAB OR (95% CI) | p-value | IGM OR (95% CI) | p-value | IGG OR (95% CI) | p-value |
|----------|------------------|---------|-----------------|---------|----------------|---------|
| Age      | 0.98 (0.95–1.02) | 0.386   | 0.98 (0.97–0.99)| 0.0004  | 1.03 (1–1.05)  | 0.0386  |
| Gender   |                  |         |                 |         |                |         |
| M vs F   | 0.65 (0.24–1.73) | 0.386   | 0.91 (0.71–1.18)| 0.4795  | 1.26 (0.75–2.13)| 0.3869  |
| Biological risk |            |         |                 |         |                |         |
| Low risk YS vs NO | not estimable |         | 0.31 (0.17–0.57) | 0.0001 | 0.41 (0.13–1.33) | 0.1395 |
| Medium risk YS vs NO | 1.32 (0.49–3.52) | 0.582   | 1.23 (0.95–1.6)  | 0.1207  | 1.44 (0.82–2.53) | 0.2086  |
| High risk YS SI vs NO | 1.03 (0.37–2.91) | 0.95   | 1.02 (0.77–1.35) | 0.9023  | 0.79 (0.42–1.48) | 0.4588  |
| Job title |                  |         |                 |         |                |         |
| Physician YS vs NO | 4.99 (1.77–14.06) | 0.002   | 1.36 (1.05–1.75) | 0.0199  | 0.87 (0.5–1.54) | 0.6362  |
| Nurse YS vs NO | 0.56 (0.18–1.71) | 0.311   | 1.09 (0.84–1.42) | 0.5078  | 0.84 (0.47–1.48) | 0.5409  |
| Support operator YS vs NO | 0.35 (0.05–2.62) | 0.305   | 0.84 (0.58–1.23) | 0.3703  | 1.97 (1.07–3.65) | 0.0302  |
| Health care professions YS vs NO | not estimable |         | 0.8 (0.32–2.02) | 0.6332  | 0.79 (0.41–1.56) | 0.8164  |
| Other YS vs NO |                  |         |                 |         |                |         |
| not estimable | 0.54 (0.36–0.83) | 0.0044  | 0.77 (0.35–1.72) | 0.2592  |                |         |
| Operative unit |                  |         |                 |         |                |         |
| Other clinical units YS vs NO | 1.97 (0.7–5.54) | 0.2   | 1.54 (1.18–2)  | 0.0013  | 1.65 (0.94–2.9) | 0.082   |
| Infectious diseases YS vs NO | not estimable |         | 0.22 (0.05–0.91) | 0.0358  | 0.59 (0.08–4.33) | 0.604   |
| Emergency room YS vs NO | 1.27 (0.17–9.61) | 0.819   | 0.29 (0.11–0.79) | 0.0155  | 1.2 (0.37–3.9)  | 0.7619  |
| Intensive care unit, anesthesiology YS vs NO | 1.65 (0.54–5.04) | 0.381   | 1.38 (1–1.92)  | 0.0504  | 0.67 (0.29–1.57) | 0.3578  |
| COVID units YS vs NO | not estimable |         | 0.41 (0.84–2.37) | 0.1921  | 1.08 (0.33–3.51) | 0.8984  |
| Nonclinical units YS vs NO | not estimable |         |                 |         |                |         |

Table 4
Multivariate analyses.

|          | IGM AdjOR (95% CI) | p-value | IGG AdjOR (95% CI) | p-value |
|----------|-------------------|---------|-------------------|---------|
| SWAB     |                  |         |                  |         |
| Positive vs Negative | 2.91 (1.01–8.39) | 0.0485  | 77.32 (26.07–229.34) | <.0001  |
| AGE      | 0.98 (0.97–1.01) | 0.0075  | 1.03 (1–1.06)  | 0.018   |
| Gender   | 0.97 (0.75–1.27) | 0.8404  | 0.73 (0.41–1.29) | 0.2751  |
| Risk     |                  |         |                  |         |
| Medium vs Low | 2.91 (1.57–5.39) | 0.0007  | 3.03 (0.9–10.21) | 0.0744  |
| High vs Low | 2.84 (1.5–5.39) | 0.0014  | 2.32 (0.62–8.62) | 0.2091  |
| Job title |                  |         |                  |         |
| Physician YS vs No | 0.97 (0.72–1.3) | 0.8454  | 0.68 (0.35–1.35) | 0.2739  |
| Operative unit |                  |         |                  |         |
| Infectious diseases | 0.2 (0.05–0.85) | 0.0289  | 0.85 (0.11–6.7) | 0.8733  |

Table 5
Accuracy of serological tests (IgM and IgG) using the SWAB test as the gold standard.

|          | IGM | IGG |
|----------|-----|-----|
| Sensitivity | 27.78% | 50.00% |
| Specificity | 88.61% | 97.99% |
| Positive Likelihood Ratio | 2.44 | 24.89 |
| Negative Likelihood Ratio | 0.82 | 0.51 |
| Ectopic prevalence | 0.75% | 0.75% |
| Positive Predictive Value | 1.81% | 15.79% |
| Negative Predictive Value | 99.39% | 99.62% |

Fig. 1. Prevalence of positive IgG results.

Fig. 2. Geometric mean values of IgG.
PCR-negative patients receiving in-center hemodialysis, suggesting that current diagnostic screening strategies may be limited in their ability to detect acute infection (Clarke et al., 2020). In our study, we found a high seroprevalence of SARS-CoV-2 with the Abbott test, but low sensitivity in identifying virus carriers and low positive predictive values in 2407 serum samples. Thus, serological tests did not adequately indicate SARS-CoV-2 infection in patients with a previous positive NST result (IgM and IgG sensitivity of 27.78% and 50.00%, respectively). These results are in contrast to those from Batra and colleagues (Batra et al., 2020), who found that the test had a specificity of 100% and sensitivity of 99.1% for specimens collected >14 days post symptom onset or >5 days post-RNA testing. On the other hand, Meschi et al. (2020) showed that the Abbott system could have lower sensitivity, which is more similar to our results (61.9% on the fourteenth day).

These results suggest that NST based on the RT-PCR method should be the gold standard for guiding decisions on quarantine and readmission to work in occupational health surveillance.

At present, serological tests cannot replace the molecular diagnostic test as they are not characterized by sufficient validity due to their low sensitivity in identifying virus carriers. Therefore, there are no recommendations for their use for both diagnostic (early identification of infected subjects) and prognostic purposes in occupational settings, nor to determine the work suitability for each worker.

Serological tests, on the other hand, are very important in the epidemiological evaluation of viral circulation in workplaces and in risk assessment. Fundamentally, they allow the estimation of the number of subjects infected, as well as tracking the spread of the diseases through a specific population, setting or environment over time. Accordingly, serological screening programs in the different hospital departments can contribute, for example, to the identification of the departments with the higher risk of virus circulation. Further investigations are required to better understand the utility of these tests in decisions regarding the return of HCWs with positive serological tests.

5. Conclusion

We found a high unexpected prevalence of SARS-CoV-2 among 2407 HCWs of University Hospital of Bari, Italy despite a low positivity rate for RT-PCR tests, which is considered the gold standard for diagnosis. These results could suggest that serological screening of SARS-CoV-2 antibodies should be implemented to better track positive HCWs but only in association with RT-PCR. Due to the low sensitivity in identifying virus carriers of the Abbott Serological Test highlighted in our study, HCWs of University Hospital of Bari, Italy despite a low positivity rate 5. Conclusion

Author contributions

Luigi Vimercati had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Conceptualization and Project administration: LV, PLL, LG, GM and ST. Data curation: DC, MQ, LDM, AC, PS, SS and AMVL. Writing (original draft & review & editing): LDM, AC and MQ. Formal analysis: GG. Methodology and Supervision: LV and ST.

Funding source

This research did not receive any specific grants from funding agencies in the public, commercial or not-for-profit sectors.

Patient consent

Informed and written consent was obtained from the participants. The patients were informed that data from the research protocol would be treated in an anonymous manner based on scientific methods and for scientific purposes in accordance with the principles of the Helsinki Declaration.

Ethical approval is not necessary because all medical and instrumental examinations were performed according to Italian laws concerning the protection of workers exposed to occupational risks (D. Lgs. 81/2008).

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

Alessio, L., Perro, S., Aparo, U.L., Bassetti, D., Beltrame, A., Buzzi, F., Cipolloni, S., Germano, T., Lombardi, R., Longo, F., et al., 2005. Linee Guida per la Sorveglianza Sanitaria dei Lavoratori della Sanit a rischio biologico. Soc. Ital. Med. Lavoro ed Igiene Ind.: PIME: Pavia, Italy ume 17.

Batra, R., Olivieri, L.G., Rubin, D., Vallari, A., Pearce, S., Olivo, A., Prontko, J., Nebbia, G., Douthwaite, S., Rodgers, M., Cloherty, G., 2020 Sep 16. A comparative evaluation between the Abbott Panbio® COVID-19 IgG/ IgM rapid test device and Abbott Architect™ SARS CoV-2 IgG assay. J. Clin. Virol. 132, 104645. https://doi.org/10.1016/j.jcv.2020.104645. Epub ahead of print. PMID: 32961429; PMCID: PMC7492757.

Bhattacharya, S., Banu, P., Poddar, S., 2020. Changing epidemiology of SARS-CoV in the context of COVID-19 pandemic. Published 2020 Jul 4 J Freq Med Hyg 61 (2), E130-E136. https://doi.org/10.11167/2421-4246/jmhp2020.61.2-1341.

Boger, B., Fachi, M.M., Vilhena, R.O., Cobre, A.F., Tonin, F.S., Pontarolo, R., 2020. Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19 [published online ahead of print, 2020 Jul 10]. Am. J. Infect. Contr. S0196-6553 (20), 30693. https://doi.org/10.1016/j.ajic.2020.07.011, 2.

Center for Disease Control. https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html.

Centre for Disease Control and Prevention. Centre for disease control and prevention: interim operational considerations for public health management of healthcare workers exposed to or with suspected or confirmed covid-19: non-u.s. healthcare settings. Available online: https://www.cdc.gov/coronavirus/2019-ncov/hcp/no-nos-settings/public-health-management-hcw-exposed.html. (Accessed 12 October 2020).

Clarke, C., Prendergast, M., Dhuia, A., et al., 2020. High prevalence of asymptomatic COVID-19 infection in haemodialysis patients detected using serologic screening [published online ahead of print, 2020 jul 30]. ASN.2020060827. J. Am. Soc. Nephrol. https://doi.org/10.1681/ASN.2020060827.

Deeks, J.J., Dienes, J., Takwoingi, Y., et al., 2020. Antibody tests for identification of current and past infection with SARS-CoV-2. Published 2020 Jun 25 Cochrane Database Syst. Rev. 6 (6), CD013652. https://doi.org/10.1002/14651858.CD013652.

WHO Recommended Surveillance Standards WHO/CDS/CSR/ISR/99-2.2. https://www.who.int/csr/resources/publications/surveillance/whocsr2cr992.pdf.

European Center for Disease Control (ECDC). https://www.ecdc.europa.eu/sites/default/files/documents/infection-prevention-and-control-in-healthcare-settings-COVID-19-4th-update.pdf.

Guedez-Lopez, G.V., Alguacil-Guillen, M., Gonzalez-Donapetry, P., et al., 2020. Evaluation of three immunochromatographic tests for rapid detection of antibodies against SARS-CoV-2 [published online ahead of print, 2020 Aug 17]. Eur. J. Clin. Microbiol. Infect. Dis. 1–9. https://doi.org/10.1007/s10096-020-04010-7.

Guideline for the Collection of Clinical Specimens during Field Investigation of Outbreaks. WHO/CDS/CSR/EDC/200.4. https://www.who.int/h Armeniae-publications/WHO_CDS_CSR_EDC_2004.4/en/.

Karupiah, A., Bhadravaj, S., Crimmins, C., Elsamadicy, E., Rabin, J., Kodali, B.S., 2020. Detection of COVID-19 IgG/IgM rapid test device and Abbott Architect™ SARS CoV-2 IgG antibody in asymptomatic and discharged patients with reoccurring positive COVID-19 nucleic acid test (RPNT) [published online ahead of print, 2020 Aug 18]. Ann. Emerg. Med. 75, 260–273. https://doi.org/10.1016/j.ajem.2020.06.008.

Lavoro ed Igiene Ind.: PIME: Pavia, Italy ume 17.

Meschi, S., Colavita, F., Bordi, L., Matusali, G., Lapa, D., Amendola, A., Vairo, F., 2020. Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19 [published online ahead of print, 2020 Jul 6]. Am. J. Infect. Contr. S0196-6553 (20), 30693. https://doi.org/10.1016/j.ajic.2020.07.011, 2.

Nicol, T., Lefeuvre, C., Serri, O., et al., 2020. Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow
immunoassay (NG Biotech). J. Clin. Virol. 129, 104511. https://doi.org/10.1016/j.jcv.2020.104511.

Padoan, A., Comai, C., Sciacovelli, L., Faggian, D., Plebani, M., 2020. Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. Clin. Chem. Lab. Med. 58 (7), 1081–1088. https://doi.org/10.1515/cclm-2020-0443.

Shibata, S., Ishiguro, T., Kobayashi, Y., et al., 2020. High incidence of false-positive results of IgG antibody against SARS-CoV-2 with rapid immunochromatographic antibody test due to human common cold coronavirus infection. Respir Med Case Rep 31, 101180. Published 2020 Jul 25.

Shu, H., Wang, S., Ruan, S., et al., 2020. Dynamic changes of antibodies to SARS-CoV-2 in COVID-19 patients at early stage of outbreak [published online ahead of print, 2020 Jul 27]. Virol. Sin. 1–8. https://doi.org/10.1007/s12250-020-00268-5.

Soleimani, R., Khourssaji, M., Gruson, D., et al., 2020. Clinical usefulness of fully automated chemiluminescent immunoassay for quantitative antibody measurements in COVID-19 patients [published online ahead of print, 2020 Aug 14]. J. Med. Virol. https://doi.org/10.1002/jmv.26430.

Tang, H., Tian, J.B., Dong, J.W., et al., 2020. Serologic detection of SARS-CoV-2 infections in hemodialysis centers: a multicenter retrospective study in wuhan, China [published online ahead of print, 2020 Jul 31], 1 Am. J. Kidney Dis. 50(272–6386 (20), 30786. https://doi.org/10.1053/j.ajkd.2020.06.086.

World Health Organization, 2018. Protocol to Investigate Non-seasonal Influenza and Other Emerging Acute Respiratory Diseases. World Health Organization, Geneva, 2018. https://www.who.int/influenza/resources/publications/outbreak_investigation_protocol/en/.

Zhang, C., Zhou, L., Liu, H., et al., 2020. Establishing A high sensitivity detection method for SARS-CoV-2 IgM/IgG and developing a clinical application of this method [published online ahead of print, 2020 aug 17]. Emerg. Microb. Infect. 1–27. https://doi.org/10.1080/22221751.2020.1811161.